PMID- 33718101
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210316
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 10
IP  - 2
DP  - 2021 Feb
TI  - A case report of complete pathological remission after chemotherapy in a patient 
      with primary renal squamous cell carcinoma.
PG  - 997-1005
LID - 10.21037/tau-20-1483 [doi]
AB  - This is the first case report of the outcomes of systemic chemotherapy in a 
      patient with locally advanced renal squamous cell carcinoma, a rare tumor, as 
      well as the first next generation sequencing study of this rare tumor. The 
      patient's main symptoms were fever and low back pain. Initial positron emission 
      tomography and computed tomography (PET-CT) suggested a malignant renal tumor at 
      onset, but biopsy confirmed renal squamous cell carcinoma. Next generation 
      sequencing showed a low level of microsatellite instability (MSI-L), a high tumor 
      mutational burden (TMB-H), a high neoantigen burden (TNB-H), and a strong loss of 
      heterozygosity (LOH) for human leukocyte antigen (HLA), with 67 deleterious 
      mutations. The patient achieved partial radiological remission after a cycle of 
      systemic chemotherapy with albumin-bound paclitaxel combined with nedaplatin. 
      After radical resection of the left renal tumor, postoperative pathology 
      confirmed complete tumor remission and tumor-like xanthogranulomatous 
      pyelonephritis. Conclusion: This renal squamous cell carcinoma patient responded 
      to systemic chemotherapy with paclitaxel combined with platinum, providing a 
      reference for the future treatment of similar cases. Pathology and gene 
      sequencing indicated that renal squamous cell carcinoma occurred in a background 
      of active inflammation and that the tumor evolved immune escape mechanisms such 
      as loss of HLA heterozygosity, with gene repair defects and TMB-H.
CI  - 2021 Translational Andrology and Urology. All rights reserved.
FAU - Yu, Haiming
AU  - Yu H
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
FAU - Yu, Lan
AU  - Yu L
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
FAU - Li, Jinying
AU  - Li J
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
FAU - Liu, Li
AU  - Liu L
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
FAU - Zhang, Xiaotao
AU  - Zhang X
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
FAU - Han, Xiaona
AU  - Han X
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
FAU - Cheng, Xi
AU  - Cheng X
AD  - Day Ward of Chemotherapy, Qingdao Central Hospital, Qingdao, China.
LA  - eng
PT  - Case Reports
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC7947427
OTO - NOTNLM
OT  - Renal squamous cell carcinoma
OT  - case report
OT  - chemotherapy
OT  - next generation sequencing
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tau-20-1483). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
PMCR- 2021/02/01
CRDT- 2021/03/15 07:07
PHST- 2021/03/15 07:07 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
PHST- 2021/02/01 00:00 [pmc-release]
AID - tau-10-02-997 [pii]
AID - 10.21037/tau-20-1483 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2021 Feb;10(2):997-1005. doi: 10.21037/tau-20-1483.